ストックスクリーナーアプリを入手
3.07
11.44%
0.36
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace
Cns Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Trimtech closes seed fund round to advance CNS therapeutics pipeline - Pharmaceutical Technology
CNSP stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com Australia
CNSP stock touches 52-week low at $2.2 amid sharp annual decline By Investing.com - Investing.com South Africa
CNS Pharmaceuticals jumps on current cash position update - MSN
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 By Investing.com - Investing.com South Africa
CNS Pharmaceuticals reports cash position of $14M as of February 26 - TipRanks
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 - Investing.com
Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan
CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference - The Globe and Mail
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - ACCESS Newswire
CNS Pharmaceuticals enacts 1-for-50 reverse stock split - Investing.com
CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com India
CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down -February 19, 2025 at 10:28 am EST - Marketscreener.com
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - StockTitan
Can This Drastic 1:50 Reverse Split Save CNS Pharmaceuticals' Nasdaq Listing? - StockTitan
CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit - TipRanks
Revolutionary Brain Barrier-Crossing Cancer Drug Takes Center Stage at GBM Summit - StockTitan
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit - Yahoo Finance
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs - Endpoints News
CNSP’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBiodexa Pharmaceuticals (NASDAQ:BDRX) - Benzinga
Does Cns Pharmaceuticals Inc (CNSP) offer a good opportunity for investors? - SETE News
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference - ACCESS Newswire
CNS Pharma's Breakthrough Brain Cancer Pipeline Takes Center Stage at Elite BIO CEO Conference - StockTitan
Key Market Driver in Generic Central Nervous System Drugs Industry 2025: Rising Incidence Of Mental Health ... - WhaTech
Ladenburg Thalmann slashes price target on Cns Pharmaceuticals Inc [CNSP] – find out why. - The DBT News
Cns Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
CNSP’s price-to-book ratio: An indicator of the company’s performance - US Post News
Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs - MSN
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic - The Business Journals
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - ACCESS Newswire
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity - ACCESS Newswire
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference - ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - ACCESS Newswire
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - ACCESS Newswire
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date - ACCESS Newswire
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering - ACCESS Newswire
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - ACCESS Newswire
1.28%
0.80%
大文字化:
|
ボリューム (24 時間):